Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 12/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16727382 | 0.85 | IRAK4 (0.43) | WNT1GSK3BDYRK1AIRAK4IRAK1 | |
| SCHEMBL17781934 | 0.85 | IRAK4 (0.43) | WNT1GSK3BDYRK1AIRAK4IRAK1 | |
| SCHEMBL16730138 | 0.80 | IRAK4 (0.43) | IRAK4IRAK1 | |
| SCHEMBL16713526 | 0.80 | IRAK4 (0.44) | IRAK4IRAK1 | |
| SCHEMBL15416036 | 0.80 | IRAK4 (0.51) | IRAK4IRAK1 | |
| SCHEMBL16713468 | 0.80 | WNT1 (0.48) | WNT1GSK3BDYRK1AIRAK4IRAK1 | |
| SCHEMBL15416691 | 0.80 | IRAK4 (0.53) | IRAK4IRAK1 | |
| SCHEMBL15431253 | 0.79 | IRAK1 (0.48) | IRAK4IRAK1 | |
| SCHEMBL15416438 | 0.78 | WNT1 (0.48) | WNT1GSK3BDYRK1AIRAK4IRAK1 | |
| SCHEMBL15416616 | 0.78 | IRAK4 (0.52) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | claimed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | claimed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | claimed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | WNT1 444/4885GSK3B 2682/4885DYRK1A 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.